Donald Trump Cuts Ozempic Prices to $199 in Massive 'Most Favoured Nation' Drug Deal

A gold-embossed coupon is a curious thing to pin a healthcare revolution on. But that is, in essence, what Donald Trump has done.

On Thursday night at the White House, the US president unveiled TrumpRx.gov, a new platform that promises 'dozens of the most commonly used prescription drugs' at 'dramatic discounts.' He presented it as a victory over 'Big Pharma price-gouging' and the peculiar American condition of paying far more than other countries for the same medicines.

The names that landed first were the ones already lodged in the public imagination: Ozempic and Wegovy, the GLP‑1 drugs that have become both a medical breakthrough and a social obsession. Trump claimed prices would tumble to $199 for some cash-paying customers, framing it as an overdue correction rather than an experiment.​

Yet the closer you look, the more TrumpRx reveals itself as something very modern: part policy, part product demo, part political theatre staged with the confidence of a man who knows a clean number beats a complicated explanation.

TrumpRx And The $199 Ozempic Hook

TrumpRx does not sell or dispense medicines. Instead, it routes people to discounts, often in the form of coupons they can take to a pharmacy counter, or links that send them to manufacturers' direct-to-consumer purchase sites. The website's own FAQ is explicit: the discounted pricing is 'only available for cash-paying patients', not for those trying to pay through insurance, and it does not count towards insurance deductibles.

That clause is not a footnote; it is the entire dividing line between who benefits and who merely watches. Most Americans have some form of prescription drug coverage, and many will discover that their co-pay, through insurance, is lower than TrumpRx's cash price, or that paying through the platform could leave them no closer to meeting an out-of-pocket maximum.

TrumpRx even nudges users to check that co-pay first, conceding, quietly, that the 'deal' may not always be the best deal.​

Still, for people without insurance, or those stuck paying full list prices, even partial relief can feel like oxygen. That is why the politics is so combustible: Trump is offering a tangible, printable object that says, in effect, 'I did this for you.'​

TrumpRx And The 'Most Favoured Nation' Drug Deal

The White House says TrumpRx is tied to a 'most favoured nation' pricing strategy, meant to push drugmakers to sell in the US at the lowest price offered in other developed nations. In its fact sheet, the administration says 40 branded medicines are available through TrumpRx and that, since 30 September 2025, Trump has announced 16 deals with major pharmaceutical manufacturers to bring US prices in line with those paid elsewhere.​

But even supportive coverage has noted how many details remain hazy: why the launch list is limited, how the TrumpRx prices compare to discounts patients can already access, and how stable the pricing will be once the headlines move on.

Politico reported the platform is supported by GoodRx, the well-known discount-coupon company, which emphasised that TrumpRx 'does not sell or dispense drugs' and instead 'facilitates consumer access' to selected discounts.​

There is an irony here that is hard to miss. Trump is pitching TrumpRx as a new public lever on drug prices, yet the mechanism, coupons and partner platforms, sits neatly within an existing private-sector model. That does not automatically make it cynical. It does, however, make it less like a clean break and more like a branded remix.

And branding is the point. Trump has put his name on a promise that will be tested in the least forgiving arena in politics: the everyday life of ordinary people trying to fill a prescription. If they walk away paying $199 instead of four figures, his argument will feel self-evident. If they hit a wall of exclusions and fine print, the rage will not be theoretical.​

For now, TrumpRx is a striking gesture aimed at an authentic grievance. Whether it becomes a lasting shift in US drug pricing, or just another artefact of the campaign-permanent presidency, will be decided at pharmacy counters, one awkward conversation at a time.